SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Wednesday's Economic News Crunch Could Tilt Markets
- NBA D-League On The Rise
- Obama Reiterates Commitment to Boost US-India Ties
- Japan Export Rebound Eases Fear of New Recession
- Australia Wheat Exporters Face Challenges: GrainCorp
- The Social Media Gaming Threat
- Stifling Anger at Work Can Kill, Survey Finds
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
- Americans Ditch Planes for Trains this Thanksgiving
- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Obama Reiterates Commitment to Boost US-India Ties
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Wednesday's Economic News Crunch Could Tilt Markets
- Call Me Crazy: Confessions of a Black Friday Shopper
- Turkey Day 101: How Well Do You Know Your Bird?
- Citi Mortgage Reveals Something the US Treasury Won't
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
![]() |
CNBC.com |
In the note, Arnold names names. She thinks Pfizer [PFE
Loading...
()
] should buy Wyeth [WYE
Loading...
()
] or Amgen [AMGN
Loading...
()
]. Quite some time ago, Deutsche Bank analyst Barbara Ryan had suggested Pfizer look at Amgen as well.
Arnold claims Pfizer has four choices:
1. Go it alone.
2. Do a big deal.
3. Do a bunch of small deals.
4. "Divest, or even become an acquisition target." (I put the fourth choice in quotes to make clear it's a direct quote from Arnold's note.)
Arnold argues that a big deal offers the clearest path toward a higher share price. By Arnold's calculation, "PFE value is $29 with a Wyeth deal (and average synergies) and $26 with Amgen." She says a Wyeth deal would add to earnings in the first year and an Amgen deal would boost profit in the second or third year.
The word she uses is "accretive," but I don't like that Wall Street word or the opposite one, "dilutive." In plain English, a deal adds to or subtracts from earnings. Arnold also names six other biotechs and eight "specialty pharmaceutical" companies that passed her team's screening process as potential PFE targets: Biogen Idec [BIIB
Loading...
()
], Celgene [CELG
Loading...
()
], Cubist [CBST
Loading...
()
], Genzyme [GENZ
Loading...
()
], Gilead Sciences [GILD
Loading...
()
], United Therapeutics [UTHR
Loading...
()
], Allergan [AGN
Loading...
()
], Cephalon [CEPH
Loading...
()
], Endo Pharmaceuticals [ENDP
Loading...
()
], Forest Laboratories [FRX
Loading...
()
], Medicines Co. [MDCO
Loading...
()
], Sciele Pharma [SCRX
Loading...
()
], Sepracor [SEPR
Loading...
()
] and Shire Pharmaceuticals [SHPGF
Loading...
()
].
If PFE doesn't make a big buy, Arnold believes the attractive dividend is at risk. At the analyst meeting, Pfizer's CFO said, "Barring a significant unforeseen event of size," the dividend can be maintained "at least at current levels."
But Arnold says, "Assuming historical levels of dividend increases (10 percent annually), PFE's free cash flow will fall to less than the dividend by 2013. This calls into question the sustainability of PFE's dividend (and dividend increases) and therefore of the stock price which it underpins."
At the meeting the CEO and CFO asserted that while they remain "open to everything," they just don't see a big acquisition that makes sense.
In her exclusive interview with Pfizer Chairman and CEO Jeff Kindler Wednesday, Maria Bartiromo asked him specifically about the idea of buying Amgen and generally about doing a "megamerger." You can watch the segments by clicking on these videos.
Credit Suisse makes a market in PFE and wants to do investment banking for the company. Separately, a Pfizer spokesman points out that the disclosures provided by Goldman Sachs, which I cited in yesterday's post, are outdated. A GS director is no longer on the Pfizer board.
Catherine Arnold is maintaining a neutral rating on PFE, but in today's note it sounds as if she's telling clients to sell it. "Pfizer shares are worth $21 in the current 'go it alone' scenario. Our price target is reduced from $26. We advocate avoiding shares of Pfizer," she writes.
Pfizer shares hit a new intra-day low this morning of $21.28 as of this writing.
Questions? Comments?









